TCRT
Alaunos Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.13
+19.01%Year over year
Reported trailing growth
- Revenue
- -50.0%
- EBITDA
- +0.2%
- EBIT
- -0.5%
- EPS
- +20.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -88.0%
- EBITDA
- +10.9%
- EBIT
- +12.2%
- Net income
- +10.8%
- EPS
- +24.7%
- Free cash flow
- +40.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026